130 related articles for article (PubMed ID: 12197225)
1. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.
Skubitz KM
Cancer Invest; 2002; 20(5-6):693-9. PubMed ID: 12197225
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.
Skubitz KM
Cancer Invest; 2003 Apr; 21(2):167-76. PubMed ID: 12743981
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer.
Skubitz KM
Invest New Drugs; 2002 Feb; 20(1):101-4. PubMed ID: 12003184
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
5. Caelyx in malignant mesothelioma: a phase II EORTC study.
Baas P; van Meerbeeck J; Groen H; Schouwink H; Burgers S; Daamen S; Giaccone G
Ann Oncol; 2000 Jun; 11(6):697-700. PubMed ID: 10942058
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
7. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of intravenous Doxil in malignant pleural mesothelioma.
Oh Y; Perez-Soler R; Fossella FV; Glisson BS; Kurie J; Walsh GL; Truong M; Shin DM
Invest New Drugs; 2000 Aug; 18(3):243-5. PubMed ID: 10958592
[TBL] [Abstract][Full Text] [Related]
9. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.
Hubert A; Lyass O; Pode D; Gabizon A
Anticancer Drugs; 2000 Feb; 11(2):123-7. PubMed ID: 10789595
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
[TBL] [Abstract][Full Text] [Related]
12. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
Uziely B; Jeffers S; Isacson R; Kutsch K; Wei-Tsao D; Yehoshua Z; Libson E; Muggia FM; Gabizon A
J Clin Oncol; 1995 Jul; 13(7):1777-85. PubMed ID: 7602367
[TBL] [Abstract][Full Text] [Related]
13. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin.
Arrieta O; Medina LA; Estrada-Lobato E; Ramírez-Tirado LA; Mendoza-García VO; de la Garza-Salazar J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):211-5. PubMed ID: 24817602
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
Rocca A; Cecconetto L; Passardi A; Melegari E; Andreis D; Monti M; Maltoni R; Sarti S; Pietri E; Schirone A; Fabbri F; Donati C; Nanni O; Fedeli A; Faedi M; Amadori D
Cancer Chemother Pharmacol; 2017 May; 79(5):863-871. PubMed ID: 28341957
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil).
Skubitz KM; Skubitz AP
Anticancer Drugs; 1998 Jan; 9(1):45-50. PubMed ID: 9491791
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
Steele JP; O'Doherty CA; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM
Ann Oncol; 2001 Apr; 12(4):497-9. PubMed ID: 11398882
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
